☆ 4.5 Editorial Material

The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All

JOURNAL OF ALZHEIMERS DISEASE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities

Jeremy A. Syrjanen et al.

Summary: Blood-based biomarkers of amyloid pathology and neurodegeneration are influenced by various factors such as age and chronic kidney disease. Multiple variables affect plasma biomarkers levels among cognitively unimpaired individuals in the general population. This information is critical for accurate interpretation of the biomarker levels and for the development of reference ranges.

ALZHEIMERS & DEMENTIA (2022)

添加到收藏夹

Editorial Material Neurosciences

A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time? Comment

Douglas R. Galasko et al.

Summary: A blood test for Alzheimer's disease is now available for clinical use in persons with cognitive impairment, but appropriate clinical evaluation and pre- and post-test counseling are necessary. Standalone use carries a risk of misinterpretation and guidelines for its appropriate use need to be developed.

JOURNAL OF ALZHEIMERS DISEASE (2022)

添加到收藏夹

Review Clinical Neurology

Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review

Jetske van der Schaar et al.

Summary: The study provides an overview of considerations regarding the disclosure of AD pathology before the onset of dementia, categorizing them into clinical, personal, and societal contexts. The literature on this topic is diverse and contradictory, with a focus on harmful effects.

ALZHEIMERS RESEARCH & THERAPY (2022)

添加到收藏夹

Editorial Material Neurosciences

Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance

Thomas K. Karikari

Summary: The recent advancements in blood-based Alzheimer's disease biomarkers have great potential. However, the clinical validation studies and therapeutic trials have mainly focused on a specific population, neglecting other ethnic and socioeconomic groups. This article emphasizes the importance of including diverse populations to fully realize the benefits of blood tests for Alzheimer's disease and highlights key factors for successful implementation of diversity programs.

JOURNAL OF ALZHEIMERS DISEASE (2022)

添加到收藏夹

Review Neurosciences

Spillover: The Approval of New Medications for Alzheimer's Disease Dementia Will Impact Biomarker Disclosure Among Asymptomatic Research Participants

Jessica Mozersky et al.

Summary: This article addresses the impact of recent FDA approvals for novel anti-amyloid medications on disclosure of biomarker results among asymptomatic research participants, and suggests improvements in messaging to meet the needs of participants.

JOURNAL OF ALZHEIMERS DISEASE (2022)

添加到收藏夹

Article Neurosciences

You've Got a Friend in Me: How Cognitively Unimpaired Older Adults Select a Study Partner to Participate with Them in Alzheimer's Disease Research

Emily A. Largent et al.

Summary: The requirement of having a study partner in AD prevention studies creates a barrier for potential participants. However, most potential participants identified someone who could serve as their study partner. They recognized the value of the role but also acknowledged the potential burdens it may entail.

JOURNAL OF ALZHEIMERS DISEASE (2022)

添加到收藏夹

Editorial Material Neurosciences

Avoiding Over-Reliance on Multi-Domain Interventions for Dementia Prevention Comment

Timothy Daly et al.

Summary: Although non-pharmacological risk reduction is seen as an alternative to targeting Alzheimer's disease pathology, over-reliance on multi-domain interventions may have limited individual impact, focus solely on later life, and overlook social determinants of dementia. Therefore, a broader debate within the research community and society about exploring different therapeutic avenues is necessary.

JOURNAL OF ALZHEIMERS DISEASE (2022)

添加到收藏夹

Article Clinical Neurology

Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light

Suzanne E. Schindler et al.

Summary: The study aimed to evaluate whether plasma biomarkers detect brain amyloidosis consistently across different racial groups. Results showed that a high-performance plasma A beta 42/A beta 40 assay may provide an accurate measure of brain amyloidosis across African American and non-Hispanic White groups, while models based on plasma p-tau181, p-tau231, and NfL may lead to disproportionate misdiagnosis of African American individuals.

NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study

Adam M. Brickman et al.

Summary: Blood-based Alzheimer's disease biomarkers show associations with pathological and clinical diagnoses, and have predictive value for future development of clinical AD, indicating their potential for incorporation into multi-ethnic community studies.

ALZHEIMERS & DEMENTIA (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial

David W. Oslin et al.

Summary: Genomic testing has the potential to improve patient outcomes by personalizing medication selection, but there are challenges in implementing it in routine clinical care, which requires considering clinical utility, informatics support, and patient and provider education.

CONTEMPORARY CLINICAL TRIALS (2021)

添加到收藏夹

Review Psychology, Clinical

Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment

Yuri E. Rybak et al.

Summary: The study aimed to reach a consensus on the concept, definition, staging model, and assessment of treatment-resistant depression (TRD). Experts recommended the use of staging models and clinical scales for evaluating depression, and identified risk factors and comorbidities as potential predictors for treatment resistance.

DEPRESSION AND ANXIETY (2021)

添加到收藏夹

Article Genetics & Heredity

African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants

Suzanne E. Schindler et al.

Summary: The study found that African Americans had lower CSF sTREM2 levels compared to non-Hispanic whites, were more likely to carry TREM2 coding variants associated with lower CSF sTREM2, and less likely to carry the rs1582763 minor allele near MS4A4A associated with higher CSF sTREM2 levels.

NEUROLOGY-GENETICS (2021)

添加到收藏夹

Editorial Material Clinical Neurology

Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease

Nuriel Moghavem et al.

ANNALS OF NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study

Kacie D. Deters et al.

Summary: This study found differences in amyloid PET between non-Hispanic White and Black participants who passed initial screening for the A4 study, with lower amyloid levels observed in Black participants. The effect of race on amyloid was strongest in the APOE epsilon 4 group, and within Black participants, those with lower percentage of African ancestry had higher amyloid levels.

NEUROLOGY (2021)

添加到收藏夹

Article Genetics & Heredity

Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists

Roy N. Alcalay et al.

GENETICS IN MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration

Elisabeth H. Thijssen et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results

Emily A. Largent et al.

PLOS ONE (2020)

添加到收藏夹

Editorial Material Clinical Neurology

Rescuing Research Participants After Alzheimer Trials Stop Early Sending Out an SOS

Emily A. Largent et al.

JAMA NEUROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

Gil D. Rabinovici et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Early adoption of pharmacogenetic testing for veterans prescribed psychotropic medications

Leland E. Hull et al.

PHARMACOGENOMICS (2019)

添加到收藏夹

Letter Medicine, General & Internal

Identification of Anonymous MRI Research Participants with Face-Recognition Software

Christopher G. Schwarz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Clinical Neurology

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease

John C. Morris et al.

JAMA NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics

Elizabeth E. Blue et al.

ALZHEIMERS & DEMENTIA (2019)

添加到收藏夹

Editorial Material Ethics

The Proactive Patient: Long-Term Care Insurance Discrimination Risks of Alzheimer's Disease Biomarkers

Jalayne J. Arias et al.

JOURNAL OF LAW MEDICINE & ETHICS (2018)

添加到收藏夹

Article Clinical Neurology

The Brain Health Registry: An internet-based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies

Michael W. Weiner et al.

ALZHEIMERS & DEMENTIA (2018)

添加到收藏夹

Article Clinical Neurology

What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the US general public

Shana D. Stites et al.

ALZHEIMERS & DEMENTIA (2018)

添加到收藏夹

Article Clinical Neurology

Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia

Fabricio Ferreira de Oliveira et al.

CURRENT ALZHEIMER RESEARCH (2018)

添加到收藏夹

Article Genetics & Heredity

Well, good luck with that: reactions to learning of increased genetic risk for Alzheimer disease

Doris T. Zallen

GENETICS IN MEDICINE (2018)

添加到收藏夹

Review Neurosciences

Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals

Richard Milne et al.

JOURNAL OF ALZHEIMERS DISEASE (2018)

添加到收藏夹

Review Neurosciences

When Patient Engagement and Research Ethics Collide: Lessons from a Dementia Forum

Julie M. Robillard et al.

JOURNAL OF ALZHEIMERS DISEASE (2017)

添加到收藏夹

Article Clinical Neurology

Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary

Gil D. Rabinovici et al.

Alzheimers & Dementia (2016)

添加到收藏夹

Review Neurosciences

Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment

Jennifer H. Lingler et al.

JOURNAL OF ALZHEIMERS DISEASE (2016)

添加到收藏夹

Article Clinical Neurology

The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease

Giuseppe Tosto et al.

JAMA NEUROLOGY (2016)

添加到收藏夹

Article Geriatrics & Gerontology

Association of Vascular Risk Factors With Cognition in a Multiethnic Sample

Brooke C. Schneider et al.

JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES (2015)

添加到收藏夹

Review Neurosciences

Psychometric Properties of a Decisional Capacity Screening Tool for Individuals Contemplating Participation in Alzheimer's Disease Research

Jennifer Burgher Seaman et al.

JOURNAL OF ALZHEIMERS DISEASE (2015)

添加到收藏夹

Article Genetics & Heredity

Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors

Jill S. Goldman et al.

GENETICS IN MEDICINE (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.